Early Stage DevelopmentThe lead program, CMP-SYNGAP-01 for SYNGAP-related disorders, is in a very early stage with a long time horizon to patient level value creation.
Neutral RatingThere is no price target on CAMP shares, and the lead program's early stage contributes to the Neutral rating.
Program RiskPotential setbacks with the CMP-SYNGAP-01 program are a key risk to the Neutral rating.